Can high pressure processing (HPP) and ultraviolet-C irradiation (UV-C) treatment preserve donor milk bioactive protein structure and function better than holder pasteurization?

高压处理 (HPP) 和紫外线 C 照射 (UV-C) 处理能否比巴氏灭菌更好地保留供乳生物活性蛋白的结构和功能？

• 批准号: 10655572
• 负责人: David Charles Dallas
• 金额: $ 37.25万
• 依托单位: OREGON STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10655572
• 关键词: Address; Adhesives; Affect; Aftercare; Anti-Bacterial Agents; Biological; Biological Assay; Ensure; Enzyme-Linked Immunosorbent Assay; Goals; Growth; Health; Human Milk; Immune system; Immunoglobulins; In Vitro; Infant; Infant Development; Infant Health; Infection; Lactoferrin; Lipase; Methods; Milk; Milk Banks; Milk Proteins; Mothers; Muramidase; Nutritional; Nutritional Study; Outcome; Peptide Hydrolases; Predisposition; Premature Infant; Process; Proteins; Proteomics; Research; Risk; Role; Safety; Shapes; Source; Techniques; Viral; Work; bile salts; donor milk; feeding; immunoregulation; improved; infant nutrition; irradiation; microbiome; nutrient absorption; nutrition; pasteurization; pathogen; preservation; pressure; programs; protein function; protein structure; ultraviolet; unpasteurized

Human milk bioactive proteins are degraded during commonly used Holder pasteurization of donor milk. Alternative processing techniques that ensure biosafety while preserving bioactive proteins are needed, particularly for at-risk preterm infants. High pressure processing (HPP) and ultraviolet-C irradiation (UV-C) treatment are known to preserve a few bioactive milk proteins, but no systematic research has identified the minimum processing parameters and their effects on the entire array of milk proteins’ structure and function. There is a critical need to perform this research. Our long-term goal is to optimize feeding practices for preterm infants to improve their health outcomes. The objectives of this research are to identify the minimum HPP and UV-C treatment conditions that achieve equivalent microbiological safety to Holder pasteurization while optimally preserving bioactive protein structure and function. Our central hypothesis is that minimal HPP and UV-C treatment conditions will better preserve donor milk bioactive proteins’ structure and function compared with Holder pasteurization. Our hypothesis is based on our work and that of others indicating that HPP and UV- C treatment preserve some bioactive proteins. The rationale for this work is that it can lead to changes in donor milk processing that can improve bioactive protein retention and possibly infant health outcomes. Aim 1. Determine treatment conditions for HPP and UV-C pasteurization that maximize bioactive protein preservation compared with Holder pasteurization. Minimal conditions for HPP and UV-C biosafety will be determined and retention of bioactive milk proteins will be compared between unpasteurized, Holder pasteurized, HPP-treated and UV-C-treated donor milk via ELISA and proteomics analyses. Our working hypothesis is that minimal-condition HPP and UV-C-treated donor milk will have higher retention of bioactive proteins than Holder pasteurized donor milk. Aim 2. Identify the extent to which preserved bioactive proteins maintain their bioactivities after treatment with HPP and UV-C pasteurization. Bioactivity will be examined in whole milk and fractionated protein extracts of unpasteurized and Holder, HPP and UV-C pasteurized donor milk. Our working hypothesis is that HPP and UV-C treated donor milk proteins will retain a higher degree of their bioactivities compared with Holder pasteurized donor milk as determined by in vitro antibacterial, anti-adhesive, antiviral and immunomodulatory assays, lipase and protease assays. We expect to have determined the extent to which minimally processed HPP and UV-C treatment preserves bioactive proteins’ structure and function compared with Holder pasteurization. The positive impact of this research will be guidance for donor milk processors on how to optimally process donor milk for feeding preterm infants and information for clinicians on how to evaluate available donor milk sources. Changes in milk processing to better preserve bioactive milk proteins could improve preterm infant health outcomes.

在常用的供体牛奶巴氏杀菌期间，人牛奶生物活性蛋白会降解。需要在保留生物活性蛋白的同时确保生物安全的替代加工技术，尤其是对于处于危险的早产儿。已知高压加工（HPP）和紫外线-C辐照（UV-C）处理可以保留一些生物活性牛奶蛋白，但是没有系统的研究确定最小加工参数及其对整个牛奶蛋白的结构和功能的影响。迫切需要进行这项研究。我们的长期目标是优化早产儿的喂养实践，以改善其健康状况。这项研究的目的是确定最低HPP和UV-C处理条件，这些治疗条件与持有人巴氏杀菌达到同等的微生物安全性，同时最佳地保留生物活性蛋白结构和功能。我们的中心假设是，与持有人巴氏杀菌相比，最小的HPP和UV-C处理条件将更好地保留供体牛奶生物活性蛋白的结构和功能。我们的假设基于我们的工作，而其他假设表明HPP和UV-C治疗可保留某些生物活性蛋白。这项工作的理由是，它可以导致供体牛奶加工的变化，从而可以改善生物活性蛋白的保留率和可能的婴儿健康结果。 AIM 1。确定HPP和UV-C巴氏杀菌的治疗条件，与持有人的巴氏杀菌相比，最大化生物活性蛋白的制剂。将确定HPP和UV-C生物安全的最小条件，并将生物活性牛奶蛋白保留在未经省剂，持有人巴氏杀菌，通过ELISA和蛋白质组学分析的UV-C-C处理的供体牛奶之间进行比较。我们的工作假设是，与持有者的巴氏灭菌供体牛奶相比，最小的HPP和UV-C处理供体牛奶的生物活性蛋白保留率更高。目的2。确定用HPP和UV-C巴氏抗性治疗后保留的生物活性蛋白保持生物活性的程度。将在全牛奶中检查生物活性，并在未经巴氏消毒和持有人，HPP和UV-C巴氏杀菌供体牛奶的分离蛋白提取物中进行检查。我们的工作假设是，与持有者巴氏杀菌供体牛奶相比，HPP和UV-C处理的供体牛奶蛋白将保留更高程度的生物活性，这是通过体外抗菌，抗粘附，抗病毒和免疫调节性测定，脂肪酶和蛋白酶分析确定的。我们预计，与持有人的巴氏杀菌相比，我们预计最小处理的HPP和UV-C处理的程度可保留生物活性蛋白的结构和功能。这项研究的积极影响将是捐赠牛奶加工商的指导，即如何处理供体牛奶为早产儿提供供体牛奶，并为临床医生提供有关如何评估可用供体牛奶源的信息。牛奶加工以更好地保存生物活性牛奶蛋白的变化可以改善早产儿的健康结果。

项目成果

Summary of the Joint National Institutes of Health and the Food and Drug Administration Workshop Titled "Exploring the Science Surrounding the Safe Use of Bioactive Ingredients in Infant Formula: Considerations for an Assessment Framework".

• DOI: 10.1016/j.jpeds.2022.11.027
• 发表时间: 2023-04
• 期刊: JOURNAL OF PEDIATRICS
• 影响因子: 5.1
• 作者: Donovan, Sharon M.;Abrams, Steven A.;Azad, Meghan B.;Belfort, Mandy B.;Bode, Lars;Carlson, Susan E.;Dallas, David C.;Hettinga, Kasper;Jarvinen, Kirsi;Kim, Jae H.;Lebrilla, Carlito B.;McGuire, Michelle K.;Sela, David A.;Neu, Josef
• 通讯作者: Neu, Josef